- Home
- FHTX
FHTX
Foghorn Therapeutics Inc.
as 06-20-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $12.63 | AVG Volume (30 days): | 121.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.94 - $10.25 | Next Earning Date: | 08-07-2025 |
| Revenue: | $23,504,000 | Revenue Growth: | -30.66% |
| Revenue Growth (this year): | 44.01% | Revenue Growth (next year): | 9.45% |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Zacks
a month ago
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
a month ago
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
PR Newswire
a month ago
Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development
GlobeNewswire
2 months ago
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewswire
2 months ago
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
GlobeNewswire
2 months ago
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
2 months ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.